Abbott announces the US launch of their IonicRF device

227

Abbott has announced that their IonicRF, a minimally invasive radiofrequency ablation device, is now being launched in the USA. This is after the IonicRF device received clearance from the US Food and Drug Administration (FDA).

IonicRF is intended for the management of pain in the nervous system. The non-surgical device uses an electrical current to heat up a small area of tissue, targeting specific nerves and blocking pain signals from reaching the brain. According to studies cited by Abbott, a single radio ablation treatment’s effects can last from six to 12 months.

Millions of people suffer from chronic pain in the USA. The most common medical complaint worldwide is lower back pain, which could potentially be treated with this device.

This is Abbotts’ first radiofrequency abolition device, which is currently approved for use in the USA and Europe.

Jason E Pope, founder and CEO of Evolve Resortation Center, Santa Rosa, USA, comments: “Every patient is different and the source of their pain is unique, making it extremely important to have multiple options available, so treatment can be tailored to individual circumstances.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here